A Phase III Study of MK-7684 with Pembrolizumab Immunotherapy (MK-7684A) versus Pembrolizumab Alone as Initial Treatment for Metastatic Non-Small Cell Lung Cancer


Full Title

A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (KEYVIBE-003)


MK-7684A is an investigational immunotherapy made up of the drugs MK-7684 and pembrolizumab. Immunotherapy works by boosting the power of the immune system to find and kill cancer cells. In this study, researchers are comparing the effectiveness of MK-7684A with pembrolizumab alone as initial treatment for people with metastatic non-small cell lung cancer (NSCLC).

Participants will be randomly assigned to receive MK-7684A or pembrolizumab. Both therapies are given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have metastatic NSCLC that makes the PD-L1 protein (the target of pembrolizumab) and cannot be treated with medications that target the EGFR, ALK, or ROS1 proteins.
  • Prior treatments must have been completed at least 6 months before the diagnosis of metastatic NSCLC. Patients may not have received treatment for metastatic disease.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Jamie Chaft at 646-608-3761.





Disease Status

Newly Diagnosed